Navigation Links
Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
Date:8/27/2009

  • The Company saw top line revenues increase 165% with growth from its Personalized Oncology and Preclinical eValuation businesses.
  • Experienced positive increases in contract signing and saw deferred revenues end the 2009 fiscal year at $1.2 million compared to $0.5 million in the prior year.
  • Continued to build out its Tumorgraft platform with nearly 200 Tumorgrafts available and/or in development at April 30, 2009 representing all the major solid tumor indications.
  • Champions' Preclinical eValuation services business was launched and completed contracts with large pharmaceutical companies to evaluate their drug candidates. The business delivered its first drug development project to a major top tier Biotech and has several other studies nearing completion.
  • The Company began its effort to build an oncology drug pipeline and completed its first royalty agreement on an oncology drug candidate with Concordia Pharmaceuticals.
  • Champions established a collaboration with Do-Coop, an Israel based biotech firm to develop a more soluble form of its SG410 drug candidate, which allowed Champions to move forward into Biomerk Tumorgraft(TM) testing.
  • The Company entered into a collaboration with Gradalis and Mary Crowley Cancer Research Center to develop personalized cancer vaccines for cancer patients.
  • The Company launched its Personal Oncology website www.personalizedcancertreatment.com and established a UK subsidiary, Champions Biotechnology, UK Ltd. and an Israel branch.

    • For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com.
    '/>"/>

    SOURCE Champions Biotechnology, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    1

    GOOD

    Page: 1 2 3 4 5

    Related biology technology :

    1. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
    2. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
    3. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
    4. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
    5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
    6. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
    7. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
    8. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
    9. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
    10. Malaysian Biotechnology Sector
    11. Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/20/2009)...ntly announced that Dr. Dominique Hebrault will pr...nalytical Technology (PAT) in Green Chemistry and ... (PRWEB) November 20, 2009 -...ology (PAT) in Green Chemistry and Green Engineeri...nology (PAT) case studies will be presented on how...
    (Date:11/19/2009)...Call/ -- Omeros Corporation (Nasdaq: OMER ) today...rd quarter ended September 30, 2009. For the three...a net loss of $3.9 million, or $1.34 per share, as...per share, for the same period in 2008. For the ni...ported a net loss of $15.5 million, or $5.29 per s...
    (Date:11/19/2009)...tCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), announ... its shareholders, discussing the Company,s acquis...icals Holdings, Inc. (CHBP), an integrated bio-pha... of China. The merger gives NeoStem a controlling ...., CHBP,s primary operating subsidiary and a promi...
    (Date:11/19/2009)...19 MONITORING FORCE GmbH,announced...nserin in the,indication treatment-relevant levodo...rphan drug status designation with the European Me... is a complication of the mainstay,treatment in ad... those,affected, since it may be disabling for the...
    Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
    ... TSX Exchange Symbol: RVX, CALGARY, Apri...Resverlogix" or the "Company") (TSX:RVX) announced...a safety, tolerability and pharmacokinetics,study ...ses the,dyslipidemia market. "Initial results from... J. McCaffrey, President & CEO of Resverlogix. "As...
    ...SM), a developer of follow-on biologics (FOBs) and...Allan, Ph.D., CEO of Insmed, will present at,the C...n FOBs, on April 29,2008 at 2:15 PM Eastern Time i..."Evaluate the Legislative, Economic and,Scientific...rs and,Follow-On Biologics," will be held at the D...
    ...oterrorism, Says UK Board Mem...fense Corp., the only company in,the world to deve...destroy,a biohazardous substance while maintaining...ounced it has partnered with General Lord Guthrie,...blish new security,markets for the BioDefense Mail...
    Other Biology Technology:Dosing for RVX-208 Phase 1a Clinical Study Completed 2Insmed to Present at CBI Follow-On Biologics Conference 2Insmed to Present at CBI Follow-On Biologics Conference 3Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection 2Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection 3
    (Date:11/22/2009)...h Centre, a partnership of the University of Briti...tal Health Research Institute, have uncovered new ...ls die following a stroke, as well as a possible w...dy were recently published online in Nature Medic...tinue to die even after blood flow has been restor...
    (Date:11/20/2009)...ad studies about the health benefits of having a l...ar level, where amino acids known as cysteines are...hen paired up with other cysteines. , Now, resea...olleagues in Belgium, have discovered a new antiox...esearch appears in the Nov. 20 issue of the journa...
    (Date:11/20/2009)...9) Scientists from the Marine Biogeochemistry and...arch Laboratory (NRL) organized and led a team of ...expedition to initiate methane hydrate exploration...iation of sediment contribution to Arctic climate ...Polar Sea as a research platform, three cross-shel...
    Breaking Biology News(10 mins):New understanding about mechanism for cell death after stroke leads to possible therapy 2Saving the single cysteine: New antioxidant system found 2International expedition investigates climate change, alternative fuels in Arctic 2100+ Nurses to Rally in SF Wed to Demand Stronger Swine Flu Safety Protections 3A California Hospitals Remain Unprepared Despite First Nurse Death 53680 1100+ Nurses to Rally in SF Wed to Demand Stronger Swine Flu Safety Protections 3A California Hospitals Remain Unprepared Despite First Nurse Death 53680 2100+ Nurses to Rally in SF Wed to Demand Stronger Swine Flu Safety Protections 3A California Hospitals Remain Unprepared Despite First Nurse Death 53680 3ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomyc 53677 1ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomyc 53677 2ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomyc 53677 3ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomyc 53677 4Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 1Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 2Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 3
    ...dentified the proteins that allow specific brain c...aks what can come into the cell. The findings, des...researchers harness the process, perhaps one day u...disease. , Much as turning the television dial cha...cells are able to change what they allow in by swa...
    ...eaded by Professor Hans-Georg Kräusslich at Heidel...Hanswalter Zentgraf, Division of Applied Tumor Vir...man Cancer Research Center, DKFZ), have been the f... for visual investigations without inhibiting the ...beling permits scientists to observe the behavior ...
    ... secreted by mussels and a polymer that repels cel...rsity have designed a versatile new two-sided coat... , Currently the longevity of certain medical imp... in the body gradually accumulate on the devices (...and threatening patients with infections. Unfortun...
    Other Biology News:Some Brain Cells Change Channels 2Some Brain Cells Change Channels 3New Species of Coral Discovered Off Southern California 2Innovative coating could give medical implants a longer life 2
    Chaperone Sampler Kit from BD Biosciences Pharmingen
    SH3 Proteins II Sampler Kit from BD Biosciences Pharmingen
    Mouse Anti-SOCS3 Monoclonal Antibody, Unconjugated, Clone SOC-25 from BioLegend
    Caveolin Sampler Kit from BD Biosciences Pharmingen
    Biology Products: